Showing results (231-240 of 255) with videos related to

Sort By:
Pageof 26
Arteriosclerosis (Dallas, Tex.)|January 1, 1989
Intralipid infusion abolishes ability of human serum to cholesterol-load cultured macrophagesM Aviram, K J Williams, R A McIntosh, et al.
Clinical Endocrinology|February 24, 2001
Choosing an oestrogen replacement therapy in young adult women with Turner syndromeH Guttmann, Z Weiner, E Nikolski, et al.
The Journal of Clinical Investigation|May 16, 1998
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonaseM Aviram, M Rosenblat, C L Bisgaier, et al.
Circulation|June 1, 2000
Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activitiesM Aviram, E Hardak, J Vaya, et al.
The American Journal of Clinical Nutrition|May 9, 2000
Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient miceM Aviram, L Dornfeld, M Rosenblat, et al.
International Journal of Hepatology|April 27, 2012
Paraoxonase activity and expression is modulated by therapeutics in experimental rat nonalcoholic Fatty liver diseaseO Hussein, J Zidan, K Abu Jabal, et al.
Chemico-Biological Interactions|July 27, 1999
On the physiological role(s) of the paraoxonasesB N La Du, M Aviram, S Billecke, et al.
Free Radical Biology & Medicine|May 8, 1999
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidantsM Aviram, M Rosenblat, S Billecke, et al.
Biochemical and Biophysical Research Communications|November 13, 1995
Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregatedM Aviram, I Maor, S Keidar, et al.
Clinical and Experimental Immunology|May 1, 1997
Oxidized low-density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS)J George, M Blank, M Hojnik, et al.
Pageof 26